Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed Aug 9, 2012 · 10-Q · 40 days after period end · 0001193125-12-345733
| Metric | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|
| Revenue | $7.76M | $23.19M | $3.21M |
| Net Income | -$14.02M | $3.12M | -$12.15M |
| EPS Diluted | -$0.13 | $0.03 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Jun 30, 2012 · filed Aug 9, 2012 · 40 d after period end
